Tiadenol
Tiadenol is an orally effective lipid-lowering compound and peroxisome proliferator. Tiadenol promotes peroxisome-associated fatty acid metabolism, and its induction of the activities of enzymes such as palmitoyl-CoA hydrolase, carnitine acetyl-transferase and catalase is mainly associated with de novo protein synthesis. The triglyceride-lowering effect of Tiadenol is not accompanied by increased activities of lipoprotein lipase (LPL) and hepatic lipase (HL), and it reduces VLDL Apo E. Tiadenol can be used in studies related to lipid metabolism, peroxisome proliferation and hyperlipoproteinemia.
For research use only. We do not sell to patients.
- CAS No.: 6964-20-1
- Formula: C14H30O2S2
- Molecular Weight:294.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Tiadenol (2-20 μM; 4 days-6 weeks) induces dose- and time-dependent increases in palmitoyl-CoA hydrolase, catalase, cyanide-insensitive palmitoyl-CoA oxidation, and carnitine acetyl-transferase activities in non-transformed C3H/10T1/2 C18 and transformed C3H/10T1/2 MCA16 mouse embryo fibroblasts, with maximal induction at 2-5 μM and effects dependent on de novo protein synthesis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tiadenol (500 mg/kg; p.o.; daily; 7 days) increases liver weight and catalase activity, decreases plasma cholesterol and total lipids, reduces biliary cholesterol concentration and output, increases bile flow and the cholesterol solubility ratio, and elevates the bile salt-independent fraction of bile secretion in normolipidemic rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 250-270 g)[3]
-
Dosage:0.27 g/day/kg body weight
-
Administration:p.o.; daily; 10 days
-
Result:Increased liver weight, hepatic protein, free CoASH, and long-chain acyl-CoA.
Increased palmitoyl-CoA hydrolase, peroxisomal palmitoyl-CoA oxidation, and total catalase activity.
Induced marked redistribution of several hepatic peroxisomal/lipid-metabolizing enzyme activities among subcellular fractions.
-
Animal Model:Wistar (male)[1]
-
Dosage:500 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Decreased plasma cholesterol and total plasma lipids.
Increased liver weight and liver catalase.
Increased basal bile flow.
Decreased biliary bile salt, phospholipid, and cholesterol concentrations and cholesterol output.
Chemical Information
-
CAS No. 6964-20-1
-
Molecular Weight 294.52
-
Formula C14H30O2S2
-
SMILES
OCCSCCCCCCCCCCSCCO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Rozé C, et al. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat. European journal of pharmacology. 1977 May 01;43(1):57-64. [Content Brief]
[2]. Franceschini G, et al. Pharmacological studies on tiadenol in type IV patients: Evidence for a mechanism of action different from other lipid-lowering drugs. Atherosclerosis. 1981;40:245-255. [Content Brief]
[4]. Berge RK, et al. Tiadenol-mediated induction of peroxisomal enzymes in cultured C3H/10T1/2 CL8 cells and in chemically transformed C3H/10T1/2 MCA16 cells. Int J Cancer. 1985;36:489-494. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tiadenol Related Classifications
HY-127055 Related Classifications
Powered by Bioz